Top 10 Companies in the Oligonucleotide Market (2025): Market Leaders Powering Global Innovation

MARKET INSIGHTS

Global oligonucleotide market was valued at USD 1.18 billion in 2025 and is expected to reach USD 2.42 billion by 2034, exhibiting a CAGR of 10.6% during the forecast period.

Oligonucleotides are short, single‑stranded DNA or RNA molecules typically consisting of 20 to 30 nucleotides. These molecules play a crucial role in various biotechnological and therapeutic applications, including gene silencing, diagnostics, and drug development. The increasing prevalence of genetic disorders and the growing demand for personalized medicine are key drivers for market growth.

Market expansion is further supported by advancements in synthesis technologies and the declining cost of oligonucleotide production. North America currently holds the largest market share due to high R&D investments and the presence of key market players. However, the Asia‑Pacific region is expected to witness the highest growth rate during the forecast period, driven by increasing healthcare expenditure and a growing biopharmaceutical sector.

Key applications driving demand include antisense oligonucleotides (ASOs) for therapeutic use, small interfering RNAs (siRNAs) for gene silencing, and CRISPR‑associated proteins for gene editing. The COVID‑19 pandemic also accelerated demand for oligonucleotides in vaccine development and diagnostic testing.

Oligonucleotide Market – View in Detailed Research Report

Top 10 Companies in the Oligonucleotide Market

1. Thermo Fisher Scientific

Headquarters: Waltham, Massachusetts, USA

Key Offering: Custom DNA/RNA synthesis, high‑throughput library preparation, and integrated analytical services.

Thermo Fisher’s automated synthesis platform enables rapid production of high‑purity oligonucleotides, supporting both research and therapeutic pipelines. The company’s recent partnership with a Singapore‑based biotech firm to develop novel oligonucleotide‑based therapies underscores its commitment to expanding the therapeutic frontier.

Sustainability & Growth Initiatives: Investment in green chemistry practices for synthesis reagents and expansion of contract manufacturing services in emerging markets.

• Automated solid‑phase synthesis platform reducing reagent waste.
• Strategic alliances with biotech startups to co‑develop therapies.
• Expansion of GMP‑compliant facilities in Asia‑Pacific.

2. Merck KGaA

Headquarters: Darmstadt, Germany

Key Offering: High‑purity phosphoramidite reagents and specialty oligonucleotides for therapeutic and diagnostic use.

Merck’s chemical synthesis expertise positions it as a leader in delivering robust oligonucleotide building blocks, enabling precision therapeutics across oncology and rare diseases.

Sustainability & Growth Initiatives: Development of recyclable synthesis reagents and digital workflow integration to streamline supply chain logistics.

• Recyclable phosphoramidite chemistry reducing waste.
• Digital platform for real‑time inventory and batch tracking.
• Collaborations with academic institutions for early‑stage discovery.

3. Danaher Corporation

Headquarters: Waltham, Massachusetts, USA

Key Offering: End‑to‑end solutions spanning oligonucleotide synthesis, purification, and analytical characterization.

Danaher’s integrated portfolio supports seamless translation from discovery to clinical development, enhancing throughput for therapeutic candidates.

Sustainability & Growth Initiatives: Automation of purification processes and expansion of cloud‑based data analytics for process optimization.

• Automated HPLC purification reducing cycle times.
• Cloud analytics for real‑time process monitoring.
• Strategic acquisitions in synthetic biology.

4. Agilent Technologies

Headquarters: Santa Clara, California, USA

Key Offering: Advanced microarray and next‑generation sequencing reagents, coupled with high‑throughput oligonucleotide synthesis.

Agilent’s expertise in sequencing and analytics complements its synthesis capabilities, offering a comprehensive platform for genomic research and diagnostics.

Sustainability & Growth Initiatives: Development of low‑energy synthesis protocols and partnerships with academic consortia to advance sequencing technologies.

• Low‑energy solid‑phase synthesis methods.
• Collaborations with genome‑editing research groups.
• Expansion of cloud‑based sequencing analytics.

5. Eurofins Scientific

Headquarters: Luxembourg

Key Offering: Fast‑turnaround GMP‑grade oligonucleotide synthesis and custom library services.

Eurofins’ reputation for rapid, high‑quality synthesis makes it a preferred partner for biotech firms seeking clinical‑grade materials.

Sustainability & Growth Initiatives: Implementation of closed‑loop water systems and waste‑reduction protocols in synthesis labs.

• Closed‑loop water recycling in synthesis facilities.
• Waste‑reduction initiatives across the supply chain.
• Strategic expansion into emerging biotech hubs.

6. Kaneka Corporation

Headquarters: Tokyo, Japan

Key Offering: Innovative oligonucleotide chemistries, including backbone modifications for enhanced stability.

Kaneka’s focus on chemically stabilized oligonucleotides supports therapeutic development in oncology and rare disease treatment.

Sustainability & Growth Initiatives: Development of biodegradable synthesis reagents and collaboration with Japanese research institutes.

• Biodegradable phosphoramidite chemistry.
• Partnerships with national research institutes.
• Expansion of local manufacturing capabilities.

7. Bio‑Rad Laboratories

Headquarters: Hercules, California, USA

Key Offering: High‑throughput oligonucleotide synthesis and diagnostics platforms.

Bio‑Rad’s integrated solutions enable rapid screening of therapeutic candidates and support diagnostic assay development.

Sustainability & Growth Initiatives: Automation of synthesis workflows and investment in renewable energy for manufacturing sites.

• Automated synthesis lines reducing manual labor.
• Renewable energy sourcing for production facilities.
• Strategic alliances with diagnostic companies.

8. OligoFactory

Headquarters: Austin, Texas, USA

Key Offering: Proprietary solid‑phase synthesis that minimizes side‑product formation.

OligoFactory’s chemistry reduces impurities, enhancing the purity of oligonucleotides for therapeutic applications.

Sustainability & Growth Initiatives: Focus on reducing chemical waste and expanding cloud‑based process control.

• Reduced impurity profile in synthesis.
• Cloud‑based batch monitoring.
• Expansion of service offerings to small biotech firms.

9. Sylentis

Headquarters: Paris, France

Key Offering: Antisense and aptamer platforms for targeted drug development.

Sylentis’s platform enables rapid design of sequence‑specific therapeutics, supporting precision medicine initiatives.

Sustainability & Growth Initiatives: Development of eco‑friendly synthesis reagents and partnership with European pharma companies.

• Eco‑friendly phosphoramidite chemistry.
• Collaboration with European pharma for pipeline development.
• Expansion of global distribution network.

10. Roche NimbleGen

Headquarters: Basel, Switzerland

Key Offering: Custom library services for CRISPR and RNA‑seq applications.

Roche NimbleGen’s library solutions support genomic research and therapeutic discovery, enhancing the speed of CRISPR‑based projects.

Sustainability & Growth Initiatives: Digital integration of library design and commitment to reducing carbon footprint in manufacturing.

• Digital library design platform.
• Carbon‑neutral manufacturing processes.
• Strategic partnerships with academic genomics consortia.

Download FREE Sample Report

Get Full Report

Future Outlook

The oligonucleotide market is poised to benefit from continued investment in RNA‑based therapeutics, with several candidates advancing through clinical trials in oncology and rare disease indications. Technological progress in synthesis and purification will further drive down production costs, while strategic collaborations between manufacturers and biotech innovators will accelerate pipeline development.

Future Trends

Key trends shaping the next decade include:

• Expansion of CRISPR‑guided guide RNA production to support gene‑editing therapies.
• Growth of point‑of‑care diagnostic platforms leveraging oligonucleotide probes.
• Increasing focus on personalized medicine, with oligonucleotides tailored to individual genomic profiles.
• Enhanced regulatory frameworks that streamline approval pathways for oligonucleotide therapeutics.